EGFR and neoplasm: BiKEs and TriKEs targeting tumor antigens HER2 [161,162,163], EGFR [164], EpCAM [165,166], B7H3 [162] and CD133 [167,168] exhibit powerful therapeutic effects against corresponding solid tumors by boosting NK immune responses in preclinical studies.